BioMarin strikes deal with Elliott, agrees to review business
BioPharma
Stay updated with breaking news from Mark Enyedy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...
BioMarin reached a settlement with activist investor Elliott Investment Management where the biotechnology company will add three independent directors to its board and form a committee to...
BioMarin Pharmaceutical Inc. , a global biotechnology company dedicated to transforming lives through genetic discovery, today announced several initiatives to enhance corporate governance and long-term shareholder...
AbbVie has signed a definitive agreement to acquire ImmunoGen, including its flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx) in a deal that is expected to speed up the former’s commercial and clinical presence in the solid tumour segment.